Blueprint
October
25, 2019
VIA EDGAR
Mses.
Effie Simpson, Theresa Brilliant and Susan Block and Mr. John Dana
Brown
United
States Securities and Exchange Commission
Division of
Corporation Finance
100 F
Street, N.E.
Washington, D.C.
20549
Re:
|
Charlie's
Holdings, Inc.
Amendment
No. 1 to Registration Statement on Form S-1 Filed September 30,
2019
File
No. 333-232596
|
Ladies
and Gentlemen:
This
letter is submitted on behalf of Charlie’s Holdings, Inc.
(the “Company”)
in response to comments of the staff of the Office of
Transportation and Leisure (the “Staff”) of the Securities and
Exchange Commission (the “Commission”) with respect to
Amendment No. 1 to the Company’s Registration Statement on
Form S-1 (the “Registration
Statement”), filed on September 30, 2019 as set forth
in your letter dated October 11, 2019 (the “Comment Letter”), addressed to
Brandon Stump, Chief Executive Officer of the Company. The Company
is filing Pre-Effective Amendment No. 2 to the Registration
Statement (the “S-1/A
No.2”) contemporaneously with the submission of this
letter to address the comments raised by the Staff in the Comment
Letter, as more particularly set forth below.
For
reference purposes, the Staff’s numbered comments have been
reproduced in bold herein, with responses immediately following
such comment. The responses provided herein are based upon
information provided to Disclosure Law Group, a Professional
Corporation, by the Company.
Form S-1/A filed September 30, 2019
Risk Factors
The regulation of tobacco products by the FDA in the United States,
page 12
1.
|
Please clarify which of Charlie's products you anticipate would be
Deemed Tobacco Products, and for which the Company may need to
cease the distribution of, if the Company does not obtain marketing
authorization, so that investor's may assess the risk. Additionally
provide disclosure in the Prospectus Summary, explaining how many
pre- market tobacco product applications you may have to file in
order to sell products after May 12, 2020, and disclosing the cost
of such applications.
|
Response
The
Company respectfully acknowledges the Staff’s comment, and
advises the Staff that the Company has revised the risk factor with
the heading “The regulation of tobacco
products by the FDA in the United States and the issuance of
Deeming Regulations may materially adversely affect the
Company” appearing on page 12 of the prospectus
contained within the S-1/A No. 2 to include disclosure regarding
the risk associated with those Charlie’s Products that may be
considered to be Deemed Tobacco Products. In addition, the Company
has revised the Prospectus Summary to include disclosure regarding
the Company’s current intentions with respect to the
submission of pre-market tobacco applications required to sell any
of its products that are considered Deemed Tobacco Products after
May 12, 2020, including the estimated costs of such
applications.
Possible yet unanticipated changes in federal and state law, page
13
2.
|
Please revise the third paragraph to explain whether the FDA
position reiterated by commissioner Scott Gottlieb on December 20,
2018 and the FDCA prohibitions discussed in this paragraph apply to
any of your products. If they do not please explain why that is the
case.
|
Response
The
Company respectfully acknowledges the Staff’s comment, and
advises the Staff that the Company has revised the risk factor with
the heading “Possible yet unanticipated
changes in federal and state law could cause any of our current
products, as well as products that we intend to launch, containing
hemp-derived CBD oil to be illegal, or could otherwise
prohibit, limit or restrict any of our products containing
CBD” appearing on page 13 of the prospectus contained
within the S-1/A No. 2 to note that, since none of the Don Polly
Products are marketed with a claim of therapeutic benefit or with
any other disease claim, the Company does not believe the Don Polly
Products fall within the FDA’s regulatory authority
reiterated by Commissioner Gottlieb in December 2018.
General
3.
|
We note you recently amended and restated your bylaws. We note that
your forum selection provision identifies a state court located
within the State of Nevada (or, if no state court located within
the State of Nevada has jurisdiction, the federal district court
for the District of Nevada) as the exclusive forum for certain
litigation, including any “derivative action.” Please
disclose whether this provision applies to actions arising under
the Securities Act or Exchange Act. If so, please also state that
there is uncertainty as to whether a court would enforce such
provision. If the provision applies to Securities Act claims,
please also state that investors cannot waive compliance with the
federal securities laws and the rules and regulations thereunder.
In that regard, we note that Section 22 of the Securities Act
creates concurrent jurisdiction for federal and state courts over
all suits brought to enforce any duty or liability created by the
Securities Act or the rules and regulations thereunder. Please
include disclosure about the exclusive forum provision in the
description of capital stock section, and include any applicable
risk factor disclosure.
|
Response
The
Company respectfully acknowledges the Staff’s comment, and
advises the Staff that the Company has revised the applicable
disclosure in the prospectus contained within the S-1/A No. 2 to
disclose that the
Company’s forum selection provision provides a state court located
within the State of Nevada (or, if no state court located within
the State of Nevada has jurisdiction, the federal district court
for the District of Nevada) with exclusive jurisdiction over only
certain matters to the “fullest extent permitted by
law”. Accordingly, this provision is not intended to apply to
claims arising under the Securities Act of 1933, as amended, for
which federal and state courts have concurrent jurisdiction, and
the Securities Exchange Act of 1934, as amended, for which federal
courts have exclusive jurisdiction. In response to the
Staff’s comment, the Company has added disclosure to page 80
of the S-1/A No. 2 to disclose the intent of the
Company’s forum selection provision. The Company has also added a risk
factor on page 18 of the Registration Statement describing the
Company’s forum selection provision and its
intent.
* *
*
We hope
that the foregoing has been responsive to the Staff’s
comments. If you have any questions or would like further
information regarding the foregoing, please do not hesitate to
contact me at (619) 272-7063.
Very
truly yours,
/s/ Jessica R. Sudweeks
Jessica
R. Sudweeks
Partner
Disclosure Law
Group, a Professional Corporation
cc:
|
Mr.
Brandon Stump
Chief
Executive Officer
Charlie’s
Holdings, Inc.
Mr.
David Allen
Chief
Financial Officer
Charlie’s
Holdings, Inc
|